D
온코크로스
382150KOSDAQ37.5 / 100
Reference Date: 2026-10-23
Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 7.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
OncoCross is a company that enhances drug development efficiency through its AI platform 'RAPTOR AI', which matches optimal diseases with therapies based on gene expression and protein data. It is also developing 'RAPTOR AI v2.0' to analyze next-generation modalities like ADC and TPD, and expanding its B2B market through the 'Neo Omics' service.
Number of Employees
40people
Average Salary
75.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
3.01Industry Average 1.200.0Point
2.5x industry avg (risky)
ROE
-52.79Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
73.51Industry Average 100.005.0Point
Lower than industry avg (good)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲503.0% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼14.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -42.6% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (3%, downtrend)
Current 3,085Won52-week high 13,87052-week low 2,685
1-month return1.0Point
1m -7.63% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral주식등의대량보유상황보고서(약식)2026-10-08
- Neutral전환가액의조정 (제1회차)2026-09-28